Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate or Darolutamide

NCT06844383 is registered in ClinicalTrials.gov with Prostate Cancer Clinical Trials Consortium as lead sponsor.

NCT NCT06844383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06844383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate or Darolutamide
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Phase
Phase 2
Overall status
Recruiting
Start date
May 4, 2026
Completion date
March 31, 2030
Enrollment
126 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc (metastatic castration-resistant prostate cancer), prostate cancer (adenocarcinoma)